Theranostics
Theranostics is a new approach to cancer treatment that combines the words “diagnostics” and “therapeutics”. This method uses molecular imaging tests, such as positron emission tomography (PET), to detect cancer cells, even in their tiny deposits. Then, radiopharmaceutical medications target the cancer cells, leaving the normal cells unharmed.
Theranostics is an effective radiation therapy for specific types of cancer, including metastatic prostate cancer and thyroid cancer. It can offer earlier diagnosis, an alternative to other treatments, more personalized treatment, and better outcomes.
Lutetium Therapy
Lu-177 is a medium-energy beta emitter with a maximum tissue penetration of less than 2mm, which provides better irradiation to small tumours without damaging the surrounding normal tissue.
It also emits gamma rays, which allow us to know the localization of the given radiopharmaceutical.
Lu-177 PSMA: Useful in patients with late-stage prostate cancer who have already taken other therapies. For the targeted treatment to work, the disease must produce the PSMA protein, which should be confirmed with a Gallium-68 PSMA PET scan.
Lu-177 DOTATE: It is used to treat gastroenteropancreatic neuroendocrine tumours that are positive for the hormone receptor somatostatin. It is an excellent option for patients who did not respond to other treatments.
Lu-177 EDTMP: Effective therapeutic agent for bone pain palliation.
Lu-177 FAPI: Clinical trials are in progress for various metastatic cancers.
BOOK A TEST